Search results
Showing 1531 to 1545 of 7680 results
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.
Prucalopride for the treatment of chronic constipation in women (TA211)
Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women.
Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.
Avapritinib for treating advanced systemic mastocytosis (TA1012)
Evidence-based recommendations on avapritinib (Ayvakyt) for treating advanced systemic mastocytosis in adults.
NICE is unable to make a recommendation on duvelisib (Copiktra) for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments because Secura Bio withdrew its evidence submission.
Show all sections
Sections for TA811
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.
View recommendations for TA199Show all sections
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin for treating chronic hepatitis C in adults.
NICE is unable to recommend the use in the NHS of bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen because no evidence submission was received from the manufacturer or sponsor of the technology.
Show all sections
Sections for TA206
NICE is unable to recommend the use in the NHS of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma because no evidence submission was received from the manufacturer or sponsor of the technology.
Show all sections
Sections for TA207